ArticleAJOG global reports2026
Care strategies for pregnant people and women living with hepatitis C in North America.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C is a global health concern, with over 50 million people infected. Marginalized populations, particularly people who inject drugs, may not receive treatment despite an increased infection rate; similarly, there are gender disparities in the hepatitis C cascade of care, leaving some women undertreated. This is especially problematic, as hepatitis C rates are increasing substantially among individuals of childbearing age and pregnant people. While hepatitis C epidemiology and baseline characteristics are well understood, models of care focused on pregnant people that provide solutions to these barriers in attaining care are needed to increase health equity and achieve hepatitis C elimination. The adoption of highly effective, direct-acting antivirals for hepatitis C treatment has helped tremendously, but direct-acting antivirals must be accessible, and their availability must be combined with enhanced screening efforts. We review newly developed models of care for pregnant people who have hepatitis C and provide several case studies (with patient examples) of methods that have improved the care cascade and patient outcomes in our practices. Some models, such as mother-infant collocated care, allow postpartum and infant hepatitis C care to occur simultaneously, minimizing the number of visits and maximizing access to patient care. Other models, such as mobile point-of-care services and peer navigation, help marginalized populations attain access to care regardless of insurance status and transportation accessibility and provide peer support to help overcome treatment barriers, such as stigma and poverty. Additional innovative hepatitis C care models for pregnant people and women include modeling-based response-guided treatment, interdisciplinary collocated care models, and an integrated medical home model. Ultimately, there is no "one size fits all" hepatitis C model of care, as needs differ according to region, population demographics, and individual circumstances. As our review shows, many of the models apply multidisciplinary approaches to provide a range of care options. Reviewing the available models of care will help identify how practitioners can increase patient engagement with care and improve treatment uptake and completion rates among pregnant people and women and thus can contribute to hepatitis C elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.